Back to results
US 11,597,759 B2Granted
Multispecific antibodies that target HIV GP120 and CD3
AssigneeGilead Sciences, Inc.
InventorsTomas Cihlar, Joshua Goldsmith, George Kukolj, Craig S. Pace, Doug Rehder, Matthew R. Schenauer, Derek Dean Sloan, Heather Theresa Stephenson, Nathan D. Thomsen
Life of this patent
Estimating the term…
Abstract
Multispecific antibodies (e.g., bispecific antibodies) that bind to HIV gp120 and CD3 are disclosed. Also disclosed are methods of using such antibodies to treat or prevent HIV infection.
Claims14
A bispecific antibody that binds to human immunodeficiency virus-1 (HIV-1) Envelope (Env) glycoprotein gp120 (gp120) and human CD3ε, wherein the antibody comprises:
- (a) a first antigen-binding domain that comprises a first heavy chain variable domain (VH) and a first light chain variable domain (VL), wherein the first antigen-binding domain binds to gp120 and comprises:
- (i) a first VH-complementarity determining region (CDR) 1 comprising the amino acid sequence of SEQ ID NO:1;
- (ii) a first VH-CDR2 comprising the amino acid sequence of SEQ ID NO:2;
- (iii) a first VH-CDR3 comprising the amino acid sequence of SEQ ID NO:3;
- (iv) a first VL-CDR1 comprising the amino acid sequence of SEQ ID NO:4;
- (v) a first VL-CDR2 comprising the amino acid sequence of SEQ ID NO:5;
- and
- (vi) a first VL-CDR3 comprising the amino acid sequence of SEQ ID NO:6, and wherein the VL comprises a tyrosine at position 67A (Kabat numbering), a phenylalanine at position 67A (Kabat numbering), a threonine at position 67A (Kabat numbering), or a glycine at position 67 (Kabat numbering);
- and
- (b) a second antigen-binding domain that binds to human CD3ε.
7 more elements
Dependencies are inferred from the claim text.